SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Pascoal A)
 

Sökning: WFRF:(Pascoal A) > Determining Amyloid...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005690naa a2200601 4500
001oai:gup.ub.gu.se/304733
003SwePub
008240528s2021 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/3047332 URI
0247 a https://doi.org/10.2967/jnumed.120.2452092 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Therriault, J.4 aut
2451 0a Determining Amyloid-β Positivity Using 18F-AZD4694 PET Imaging
264 c 2020-07-31
264 1b Society of Nuclear Medicine,c 2021
520 a Amyloid-β deposition into plaques is a pathologic hallmark of Alzheimer disease appearing years before the onset of symptoms. Although cerebral amyloid-β deposition occurs on a continuum, dichotomization into positive and negative groups has advantages for diagnosis, clinical management, and population enrichment for clinical trials. 18F-AZD4694 (also known as 18F-NAV4694) is an amyloid-β imaging ligand with high affinity for amyloid-β plaques. Despite being used in multiple academic centers, no studies have assessed a quantitative cutoff for amyloid-β positivity using 18F-AZD4694 PET. Methods: We assessed 176 individuals [young adults (n = 22), cognitively unimpaired elderly (n = 89), and cognitively impaired (n = 65)] who underwent amyloid-β PET with 18F-AZD4694, lumbar puncture, structural MRI, and genotyping for APOEε418F-AZD4694 values were normalized using the cerebellar gray matter as a reference region. We compared 5 methods for deriving a quantitative threshold for 18F-AZD4694 PET positivity: comparison with young-control SUV ratios (SUVRs), receiver-operating-characteristic (ROC) curves based on clinical classification of cognitively unimpaired elderly versus Alzheimer disease dementia, ROC curves based on visual Aβ-positive/Aβ-negative classification, gaussian mixture modeling, and comparison with cerebrospinal fluid measures of amyloid-β, specifically the Aβ42/Aβ40 ratio. Results: We observed good convergence among the 4 methods: ROC curves based on visual classification (optimal cut point, 1.55 SUVR), ROC curves based on clinical classification (optimal cut point, 1.56 SUVR) gaussian mixture modeling (optimal cut point, 1.55 SUVR), and comparison with cerebrospinal fluid measures of amyloid-β (optimal cut point, 1.51 SUVR). Means and 2 SDs from young controls resulted in a lower threshold (1.33 SUVR) that did not agree with the other methods and labeled most elderly individuals as Aβ-positive. Conclusion: Good convergence was obtained among several methods for determining an optimal cutoff for 18F-AZD4694 PET positivity. Despite conceptual and analytic idiosyncrasies linked with dichotomization of continuous variables, an 18F-AZD4694 threshold of 1.55 SUVR had reliable discriminative accuracy. Although clinical use of amyloid PET is currently by visual inspection of scans, quantitative thresholds may be helpful to arbitrate disagreement among raters or in borderline cases. © 2021 by the Society of Nuclear Medicine and Molecular Imaging.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Psykiatri0 (SwePub)302152 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Psychiatry0 (SwePub)302152 hsv//eng
653 a 18F-AZD4694
653 a Alzheimer disease
653 a amyloid-β
653 a PET
7001 a Benedet, A. L.4 aut
7001 a Pascoal, T. A.4 aut
7001 a Savard, M.4 aut
7001 a Ashton, Nicholas J.u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xashtn
7001 a Chamoun, M.4 aut
7001 a Tissot, C.4 aut
7001 a Lussier, F.4 aut
7001 a Kang, M. S.4 aut
7001 a Bezgin, G.4 aut
7001 a Wang, T.4 aut
7001 a Fernandes-Arias, J.4 aut
7001 a Massarweh, G.4 aut
7001 a Vitali, P.4 aut
7001 a Zetterberg, Henrik,d 1973u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xzethe
7001 a Blennow, Kaj,d 1958u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xbleka
7001 a Saha-Chaudhuri, P.4 aut
7001 a Soucy, J. P.4 aut
7001 a Gauthier, S.4 aut
7001 a Rosa-Neto, P.4 aut
7102 a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi4 org
7730 t Journal of nuclear medicine : official publication, Society of Nuclear Medicined : Society of Nuclear Medicineg 62:2, s. 247-252q 62:2<247-252x 1535-5667
7730 t Journal of Nuclear Medicined : Society of Nuclear Medicineg 62:2, s. 247-252q 62:2<247-252x 0161-5505x 2159-662X
8564 u https://jnm.snmjournals.org/content/jnumed/62/2/247.full.pdf
8564 8u https://gup.ub.gu.se/publication/304733
8564 8u https://doi.org/10.2967/jnumed.120.245209

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy